Company / Working Capital
Vivos Therapeutics, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
-$13.7M
FY2025
5-year range
-$13.7M / $19.8M
FY2021-FY2025
Trend
-648.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital changed -649% YoY in FY2025, a notable deviation from the 5-year average annual change of -84%.
Based on SEC 10-K filings.
-$14M in FY2025.
Declined from -$1M to -$14M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, working capital decreased 648.8% year-over-year.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$13.7M | -648.8% |
| FY2024 | $2.5M | +279.6% |
| FY2023 | -$1.4M | +0.0% |
| FY2022 | -$1.4M | -107.0% |
| FY2021 | $19.8M | +57.6% |
| FY2020 | $12.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026